imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.
tekturna
novartis europharm ltd. - aliskiren - hipertensiune - agenți care acționează asupra sistemului renină-angiotensină - tratamentul hipertensiunii esențiale.
togesic- solutie injectabila 30 mg/ml
plethico pharmaceuticals ltd - ketorolacum - solutie injectabila - 30 mg/ml
barsidon 300 mg/12,5 mg comprimate filmate
grand medical group ag - irbesartanum + hydrochlorothiazidum - comprimate filmate - 300 mg/12,5 mg
barsidon 150 mg/12,5 mg comprimate filmate
grand medical group ag - irbesartanum + hydrochlorothiazidum - comprimate filmate - 150 mg/12,5 mg
stelfonta
qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - câini - pentru tratamentul non-rezecabile, non-metastatic (care de intermediere) subcutanat de celule catarg tumori localizate la nivelul sau distal de cot sau genunchi, și non-rezecabile, non metastaze cutanate tumorile mastocitare în câini.
uroflow 2 2 mg comprimate filmate
zentiva k.s. - tolterodinum - comprimate filmate - 2 mg
panklav comprimate filmate 250 mg + 125 mg
hemofarm ad - kalii + acid clavulanicum - comprimate filmate - 250 mg + 125 mg
panklav comprimate filmate 500 mg + 125 mg
hemofarm ad - kalii + acid clavulanicum - comprimate filmate - 500 mg + 125 mg
panklav comprimate filmate 875 mg + 125 mg
hemofarm ad - kalii + acid clavulanicum - comprimate filmate - 875 mg + 125 mg